Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

CONCLUSIONS: In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.PMID:35664535 | PMC:PMC9164243 | DOI:10.1002/rth2.12736

Source: Thrombosis and Haemostasis - June 6, 2022 Category: Hematology Authors: Javier Trujillo-Santos Dominique Farge-Bancel Jos é María Pedrajas Covadonga G ómez-Cuervo Aitor Ballaz Andrei Braester Isabelle Mah é Aurora Villalobos Jos é Antonio Porras Manuel Monreal RIETE Investigators Source Type: research